MedTrace Logo

68Ga-PSMA PET in the Renal Cell Carcinoma

NCT04987086 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-03-11

No results posted yet for this study

Summary

The primary research purpose is to evaluate the diagnostic efficacy of 68Ga-PSMA PET in metastatic lesions of locally advanced and advanced renal cell carcinoma, and to compare with that of enhanced CT. The second purpose is to evaluate whether 68Ga-PSMA PET can change the treatment decision of patients with locally advanced and advanced renal cell carcinoma

Conditions

Interventions

DIAGNOSTIC_TEST

PSMA PET

PSMA PET may have influence on the clinical decision-making of the patients with renal cancer

Sponsors & Collaborators

  • Air Force Military Medical University, China

    collaborator OTHER

  • Shaanxi Provincial People's Hospital

    collaborator OTHER

  • Yan'an University Affiliated Hospital

    collaborator OTHER

  • Weinan Central Hospital

    collaborator OTHER

  • The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

    collaborator UNKNOWN

  • LanZhou University

    collaborator OTHER

  • Affiliated Hospital of Qinghai University

    collaborator OTHER

  • General Hospital of Ningxia Medical University

    collaborator OTHER

  • Xijing Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2026-12-01
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04987086 on ClinicalTrials.gov